グローバルナビゲーションへ

本文へ

ローカルナビゲーションへ

フッターへ



ホーム >  診療科・部門 >  内科 >  三室淳 著作紹介

三室淳 著作紹介


ページ内目次


最近の著書

  1. 三室 淳:分担執筆 医学書院 医学大辞典 伊藤正男、井村裕夫、高久史麿 編集 2003年 医学書院 東京
  2. 三室 淳:分担執筆 血液の事典 平井久丸、押味和夫、坂田洋一 編 朝倉書店 2004.
  3. 三室 淳:分担執筆 血液内科 診療マニアル 高久史麿 監修 小澤敬也、坂田洋一 編集 日本医学館 2004.
  4. 三室 淳:分担執筆 イラスト血液内科 第2版 溝口秀昭 編集 文光堂、2004.
  5. 三室 淳:分担執筆 VI凝固・線溶系 Annual Review血液2005 p 296-302.2005.
  6. 三室 淳:分担執筆 Annual Review 血液 編集 高久史麿、溝口秀昭、坂田洋一、金倉 譲、小嶋勢二 中外医学社 2007.1/25
  7. 三室 淳:分担執筆 講義録 血液・造血器疾患学 (小澤敬也、直江知樹、坂田洋一 編集) メジカルビュー社2008,11/10
  8. 三室 淳:分担執筆 VI凝固・線溶系 Annual Review血液2011 p216-225.
  9. 三室 淳:分担執筆 今日の診断指針 第6版 p 1125-1127 2010 医学書院 東京
  10. 三室 淳:分担執筆 小児生体肝移植 (編集:河原崎秀雄、安田是和、小林英司)日本医学館 2010
  11. 三室 淳:分担執筆 今日の治療指針 p 613-618 医学書院 2011
  12. 三室 淳:分担執筆 症候群ハンドブック (総編集:井村裕夫、編集:福井次矢・辻省次) 2011
  13. 三室 淳:分担執筆 血液内科ゴールデンハンドブック(編集:小澤敬也、坂田洋一) 2011
  14. 三室 淳:分担執筆 Annual Review血液 2011中外医学社 2011.
  15. 三室 淳:分担執筆 今日の治療指針2011 (総編集 山口徹、北原光夫、福井次矢)医学書院 東京

業績

  1. Eguchi, Y., Gando, S., Ishikura, H., Saitoh, D., Mimuro, J., Takahashi, H., Kitajima, I., Tsuji, H., Matsushita, T., Tsujita, R., et al. 2014. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intensive Care 2:30.Shirahata A, Mimuro J, Takahashi H, Tsuji H, Kitajima I, Matsushita T, et al. Postmarketing Surveillance of Recombinant Human Soluble Thrombomodulin (Thrombomodulin alpha) in Pediatric Patients With Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2014 Feb 20; 20(5):465-72.
  2. Sanada Y, Sasanuma H, Sakuma Y, Morishima K, Kasahara N, Kaneda Y, Miki A, Fujiwara T, Shimizu A, Hyodo, M, Hirata, Y. Yamada N, Okada N. Ihara Y, Urahashi T, Madoiwa S, Mimuro J, Mizuta K, Yasuda Y. et al. Living donor liver transplantation from an asymptomatic donor with mild coagulation factor IX deficiency: Report of a case. Pediatr Transplant. 2014 Dec;18(8):E270-3.
  3. Sakata A, Ohmori T, Nishimura S, Suzuki H, Madoiwa S, Mimuro J, et al. Paxillin is an intrinsic negative regulator of platelet activation in mice. Thromb J. 2014;12(1):1.
  4. Mimuro J, Mizukami H, Shima M, Matsushita T, Taki M, Muto S, et al. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol. 2014 Nov;86(11):1990-7.
  5. Matsushita T, Watanabe J, Honda G, Mimuro J, Takahashi H, Tsuji H, et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res. 2014 May;133(5):772-81.
  6. Koyama K, Madoiwa S, Nunomiya S, Koinuma T, Wada M, Sakata A, Ohmori T, Mimuro, J., Nunomiya S, and Sakata Y. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care. 2014;18(1):R13.
  7. Asakura H, Takahashi H, Tsuji H, Matsushita T, Ninomiya H, Honda G, Mimuro, J. et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy. Thromb Res. 2014 Mar;133(3):364-70.
  8. Yasumoto A, Madoiwa S, Kashiwakura Y, Ishiwata A, Ohmori T, Mizukami H, Ozawa, K., Sakata, Y., and Mimuro, J. Overexpression of factor VII ameliorates bleeding diathesis of factor VIII-deficient mice with inhibitors. Thromb Res. 2013 May;131(5):444-9.
  9. Shirahata A, Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, et al. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation. Eur J Pediatr. 2013 Sep 5.
  10. Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res. 2013 May;131(5):436-43.
  11. Mimuro J, Mizukami H, Hishikawa S, Ikemoto T, Ishiwata A, Sakata A, et al. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther. 2013 Feb;21(2):318-23.
  12. Makino N, Madoiwa S, Ohmori T, Katoh K, Ookawara S, Kanazawa T, Matsuo, O., Ichikawa, M., Mimuro, J., Ichimura, K., et al. Tissue plasminogen activator deficiency promotes early phase regeneration in the olfactory epithelium after bulbectomy. Int Forum Allergy Rhinol. 2013 Jun;3(6):458-67.
  13. Madoiwa S, Kitajima I, Ohmori T, Sakata Y, Mimuro J. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products. Thromb Res. 2013 Oct;132(4):457-64.
  14. Koyama K, Madoiwa S, Tanaka S, Koinuma T, Wada M, Sakata A, Ohmori, T., Mimuro, J., Nunomiya, S., and Sakata, Y. Evaluation of hemostatic biomarker abnormalities that precede platelet count decline in critically ill patients with sepsis. J Crit Care. 2013 Oct;28(5):556-63.
  15. Ashizawa M, Kimura S, Wada H, Sakamoto K, Sato M, Terasako K, Kikuchi, M., Nakasone, H., Okuda, S., Kako, S Yamazaki, R. Oshima, K. Matsuura, K. Ohmori, T. Madoiwa, S. Nishida, J. Ohmori, T., Mimuro, J., et al. Acquired factor V inhibitor associated with life-threatening bleeding and a mixing test result that indicated coagulation factor deficiency. Hematology. 2013 Sep;18(5):300-4.
  16. Suzuki S, Iwamoto M, Saito Y, Fuchimoto D, Sembon S, Suzuki M, Mikawa, S., Hashimoto, M., Aoki, Y., Najima, Y. Takagi, S. Suzuki, N. Suzuki, E.Kubo, M. Mimuro, J. Kashiwakura, Y. Madoiwa, S. Sakata, Y. Perry, A. C. Ishikawa, F. Onishi, A. Il2rg gene-targeted severe combined immunodeficiency pigs. Cell Stem Cell. 2012 Jun 14;10(6):753-8.
  17. Ohmori T, Yano Y, Sakata A, Ikemoto T, Shimpo M, Madoiwa S, Katsuki, T., Mimuro, J., Shimada, K., Kario, K et al. Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. Thromb Res. 2012 Apr;129(4):e36-40.
  18. Norimatsu Y, Ohmori T, Kimura A, Madoiwa S, Mimuro J, Seichi A, et al. FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms. Am J Pathol. 2012 Apr;180(4):1625-35.
  19. Kashiwakura Y, Mimuro J, Onishi A, Iwamoto M, Madoiwa S, Fuchimoto D, et al. Porcine model of hemophilia A. PLoS One. 2012;7(11):e49450.
  20. Watanabe H, Madoiwa S, Sekiya H, Nagahama Y, Matsuura S, Kariya Y, et al. Predictive blood coagulation markers for early diagnosis of venous thromboembolism after total knee joint replacement. Thromb Res. 2011 Aug 10.
  21. Madoiwa S, Tanaka H, Nagahama Y, Dokai M, Kashiwakura Y, Ishiwata A, Sakata, A., Yasumoto, A., Ohmori, T., Mimuro, J.et al. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation. Thromb Res. 2011 Apr;127(4):349-55.
  22. Dokai M, Madoiwa S, Yasumoto A, Kashiwakura Y, Ishiwata A, Sakata A, Makino, N., Ohmori, T., Mimuro, J., and Sakata, Y. et al. Local regulation of neutrophil elastase activity by endogenous alpha1-antitrypsin in lipopolysaccharide-primed hematological cells. Thromb Res. 2011 Sep;128(3):283-92.
  23. Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Honda S, et al. Vinculin activates inside-out signaling of integrin alphaIIbbeta3 in Chinese hamster ovary cells. Biochem Biophys Res Commun. 2010 Sep 24;400(3):323-8.
  24. Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Furukawa Y, et al. Vinculin is indispensable for repopulation by hematopoietic stem cells, independent of integrin function. J Biol Chem. 2010 Oct 8;285(41):31763-73.
  25. Mimuro J, Mizuta K, Kawano Y, Hishikawa S, Hamano A, Kashiwakura Y, et al. Impact of acute cellular rejection on coagulation and fibrinolysis biomarkers within the immediate post-operative period in pediatric liver transplantation. Pediatr Transplant. 2010 May;14(3):369-76.
  26. Ishiwata A, Mimuro J, Mizukami H, Kashiwakura Y, Yasumoto A, Sakata A, et al. Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques. Thromb Res. 2010 Jun;125(6):533-7.
  27. Madoiwa S, Yamauchi T, Kobayashi E, Hakamata Y, Dokai M, Makino N, Kashiwakura, Y., Ishiwata, A., Ohmori, T., Mimuro, J., et al. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A. J Thromb Haemost. 2009 May;7(5):811-24.
  28. Ishiwata A, Mimuro J, Mizukami H, Kashiwakura Y, Takano K, Ohmori T, et al. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice. J Gene Med. 2009 Nov;11(11):1020-9.
  29. Yano Y, Ohmori T, Hoshide S, Madoiwa S, Yamamoto K, Katsuki T, Mitsuhashi, T., Mimuro, J., Shimada, K., Kario, K. et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Eur Heart J. 2008 Jul;29(14):1729-38.
  30. Ohmori T, Ishiwata A, Kashiwakura Y, Madoiwa S, Mitomo K, Suzuki H, Hasegawa, M., Mimuro, J., and Sakata, Y. Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets. Mol Ther. 2008 Aug;16(8):1359-65.
  31. Niwa K, Mimuro J, Miyata M, Sugo T, Ohmori T, Madoiwa S, et al. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule. Thromb Res. 2008;121(6):773-80.
  32. Mimuro J, Niimura M, Kashiwakura Y, Ishiwata A, Ono T, Ohmori T, et al. Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxinemia. Thromb Res. 2008;122(1):91-7.
  33. Kimura A, Ohmori T, Kashiwakura Y, Ohkawa R, Madoiwa S, Mimuro J, et al. Antagonism of sphingosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain. Stroke. 2008 Dec;39(12):3411-7.
  34. Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Sakata Y. Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence. Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2266-72.
  35. Madoiwa S, Someya T, Hironaka M, Kobayashi H, Ohmori T, Mimuro J, et al. Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis. Thromb Res. 2007;119(2):229-40.
  36. Kimura A, Ohmori T, Ohkawa R, Madoiwa S, Mimuro J, Murakami T, et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells. 2007 Jan;25(1):115-24.
  37. Ito T, Okada T, Mimuro J, Miyashita H, Uchibori R, Urabe M, et al. Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Hypertension. 2007 Sep;50(3):531-6.
  38. Sugo T, Endo H, Matsuda M, Ohmori T, Madoiwa S, Mimuro J, et al. A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost. 2006 Aug;4(8):1738-46.
  39. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006 Jan 15;107(2):528-34.
  40. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006 Jun;4(6):1271-8.
  41. Ohmori T, Mimuro J, Takano K, Madoiwa S, Kashiwakura Y, Ishiwata A, et al. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J. 2006 Jul;20(9):1522-4.
  42. Ogura T, Mizukami H, Mimuro J, Madoiwa S, Okada T, Matsushita T, et al. Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer. J Gene Med. 2006 Aug;8(8):990-7.
  43. Mizukami H, Mimuro J, Ogura T, Okada T, Urabe M, Kume A, et al. Adipose tissue as a novel target for in vivo gene transfer by adeno-associated viral vectors. Hum Gene Ther. 2006 Sep;17(9):921-8.
  44. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006 Dec;84(5):398-405.
  45. Ishiwata A, Mimuro J, Kashiwakura Y, Niimura M, Takano K, Ohmori T, et al. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. Thromb Res. 2006;118(5):627-35.
  46. Ishida T, Kitamura K, Tanaka H, Ichimura K, Mimuro J, Madoiwa S, et al. Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder. Auris Nasus Larynx. 2006 Jun;33(2):187-90.
  47. Sejima T, Madoiwa S, Mimuro J, Sugo T, Okada K, Ueshima S, et al. Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol. 2005 Jun 15;174(12):8135-43.
  48. Mimuro J, Sakata Y. [Gene therapy for hemophilia]. Nippon Rinsho. 2005 Dec;63 Suppl 12:646-54.
  49. Hamano A, Umeda M, Ueno Y, Tanaka S, Mimuro J, Sakata Y. Latex immunoturbidimetric assay for soluble fibrin complex. Clin Chem. 2005 Jan;51(1):183-8.
  50. Sejima T, Madoiwa S, Mimuro J, Sugo T, Ishida T, Ichimura K, et al. Expression profiles of fibrinolytic components in nasal mucosa. Histochem Cell Biol. 2004 Jul;122(1):61-73.
  51. Ogata K, Mimuro J, Kikuchi J, Tabata T, Ueda Y, Naito M, et al. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy. Gene Ther. 2004 Feb;11(3):253-9.
  52. Mimuro J, Mizukami H, Ono F, Madoiwa S, Terao K, Yoshioka A, et al. Specific detection of human coagulation factor IX in cynomolgus macaques. J Thromb Haemost. 2004 Feb;2(2):275-80.
  53. Madoiwa S, Yamauchi T, Hakamata Y, Kobayashi E, Arai M, Sugo T, Mimuro, J., and Sakata, Y. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. J Thromb Haemost. 2004 May;2(5):754-62.
  54. Kikuchi J, Mimuro J, Ogata K, Tabata T, Ueda Y, Ishiwata A, et al. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. J Gene Med. 2004 Oct;6(10):1049-60.
  55. Hamano A, Mimuro J, Aoshima M, Itoh T, Kitamura N, Nishinarita S, et al. Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of gammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism. Blood. 2004 Apr 15;103(8):3045-50.
  56. Naito M, Mimuro J, Endo H, Madoiwa S, Ogata K, Kikuchi J, et al. Defective sorting to secretory vesicles in trans-Golgi network is partly responsible for protein C deficiency: molecular mechanisms of impaired secretion of abnormal protein C R169W, R352W, and G376D. Circ Res. 2003 May 2;92(8):865-72.
  57. Mimuro J, Hamano A, Tanaka T, Madoiwa KS, Sugo T, Matsuda M, et al. Hypofibrinogenemia caused by a nonsense mutation in the fibrinogen Bbeta chain gene. J Thromb Haemost. 2003 Nov;1(11):2356-9.
  58. Mimuro J, Muramatsu S, Hakamada Y, Mori K, Kikuchi J, Urabe M, et al. Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter. Gene Ther. 2001 Nov;8(22):1690-7.
  59. Madoiwa S, Nakamura Y, Mimuro J, Furusawa S, Koyama T, Sugo T, et al. Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversion. Blood. 2001 Jun 15;97(12):3783-9.
  60. Sugo T, Nakamikawa C, Yoshida N, Niwa K, Sameshima M, Mimuro J, et al. End-linked homodimers in fibrinogen Osaka VI with a B beta-chain extension lead to fragile clot structure. Blood. 2000 Dec 1;96(12):3779-85.
  61. Sugo T, Nakamikawa C, Takano H, Mimuro J, Yamaguchi S, Mosesson MW, et al. Fibrinogen Niigata with impaired fibrin assembly: an inherited dysfibrinogen with a Bbeta Asn-160 to Ser substitution associated with extra glycosylation at Bbeta Asn-158. Blood. 1999 Dec 1;94(11):3806-13.
  62. Mimuro J, Kawata Y, Niwa K, Muramatsu S, Madoiwa S, Takano H, et al. A new type of Ser substitution for gamma Arg-275 in fibrinogen Kamogawa I characterized by impaired fibrin assembly. Thromb Haemost. 1999 Jun;81(6):940-4.
  63. Madoiwa S, Komatsu N, Mimuro J, Kimura K, Matsuda M, Sakata Y. Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation. Blood. 1999 Jul 15;94(2):475-82.
  64. Yasuda T, Sakata Y, Madoiwa S, Mimuro J, Matsuda M, Kitamura K. Fibrinolytic components in nasal mucosa and nasal secretion. Histochem Cell Biol. 1998 Nov;110(5):449-55.
  65. Arai K, Madoiwa S, Mimuro J, Asakura S, Matsuda M, Sako T, et al. Role of the kringle domain in plasminogen activation with staphylokinase. J Biochem. 1998 Jan;123(1):71-7.
  66. Madoiwa S, Arai K, Ueda Y, Ishizuka M, Mimuro J, Asakura S, et al. A battery of monoclonal antibodies that induce unique conformations to evolve cryptic but constitutive functions of plasminogen. J Biochem. 1997 Feb;121(2):278-87.
  67. Funayama H, Sakata Y, Kitagawa S, Ikeda U, Takahashi M, Masuyama J, et al. Monocytes modulate the fibrinolytic balance of endothelial cells. Thromb Res. 1997 Mar 1;85(5):377-85.
  68. Niwa K, Takebe M, Sugo T, Kawata Y, Mimuro J, Asakura S, et al. A gamma Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Blood. 1996 Jun 1;87(11):4686-94.
  69. Kawata Y, Mimuro J, Kaneko M, Shimada K, Sakata Y. Expression of plasminogen activator inhibitor 2 in the adult and embryonic mouse tissues. Thromb Haemost. 1996 Oct;76(4):569-76.
  70. Arai K, Mimuro J, Madoiwa S, Matsuda M, Sako T, Sakata Y. Effect of staphylokinase concentration of plasminogen activation. Biochim Biophys Acta. 1995 Aug 17;1245(1):69-75.
  71. Mori K, Wada Y, Mimuro J, Matsuda M, Yoshikuni Y, Kimura K, et al. Effect of glycosidase inhibitors on the biosynthesis of alpha 2-plasmin inhibitor and antithrombin III in Hep G2 cells. Biochim Biophys Acta. 1994 Jul 18;1226(3):300-6.
  72. Watanabe T, Araki M, Mimuro J, Tamada T, Sakata Y. Fibrinolytic components in fetal membranes and amniotic fluid. Am J Obstet Gynecol. 1993 Apr;168(4):1283-9.
  73. Mimuro J, Muramatsu S, Kurano Y, Uchida Y, Ikadai H, Watanabe S, et al. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistry. 1993 Mar 9;32(9):2314-20.
  74. Mimuro J, Muramatsu S, Kaneko M, Yoshitake S, Iijima K, Nakamura K, et al. An abnormal protein C (protein C Yonago) with an amino acid substitution of Gly for Arg-15 caused by a single base mutation of C to G in codon 57 (CGG-->GGG). Deteriorated calcium-dependent conformation of the gamma-carboxyglutamic acid domain relevant to a thrombotic tendency. Int J Hematol. 1993 Jan;57(1):9-14.
  75. Mimuro J, Muramatsu S, Maekawa H, Sakata Y, Kaneko M, Yoshitake S, et al. Gene analyses of abnormal fibrinogens with a mutation in the gamma chain. Int J Hematol. 1992 Oct;56(2):129-34.
  76. Mimuro J, Kaneko M, Murakami T, Matsuda M, Sakata Y. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1. Biochim Biophys Acta. 1992 Dec 28;1160(3):325-34.
  77. Kaneko M, Sakata Y, Matsuda M, Mimuro J. Interactions between the finger and kringle-2 domains of tissue-type plasminogen activator and plasminogen activator inhibitor-1. J Biochem. 1992 Feb;111(2):244-8.
  78. Wagner SL, Lau AL, Nguyen A, Mimuro J, Loskutoff DJ, Isackson PJ, et al. Inhibitors of urokinase and thrombin in cultured neural cells. J Neurochem. 1991 Jan;56(1):234-42.
  79. Kaneko M, Mimuro J, Matsuda M, Sakata Y. The plasminogen activator inhibitor-1 binding site in the kringle-2 domain of tissue-type plasminogen activator. Biochem Biophys Res Commun. 1991 Aug 15;178(3):1160-6.
  80. Seiffert D, Mimuro J, Schleef RR, Loskutoff DJ. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ Dev. 1990 Dec 2;32(3):287-92.
  81. Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol. 1990 Jan;110(1):155-63.
  82. Sakata Y, Eguchi Y, Mimuro J, Matsuda M, Sumi Y. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor. Blood. 1989 Dec;74(8):2692-7.
  83. Mimuro J, Sawdey M, Hattori M, Luskutoff DJ. cDNA for bovine type 1 plasminogen activator inhibitor (PAI-1). Nucleic Acids Res. 1989 Nov 11;17(21):8872.
  84. Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem. 1989 Jan 15;264(2):936-9.
  85. Mimuro J, Loskutoff DJ. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem. 1989 Mar 25;264(9):5058-63.
  86. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
  87. Campochiaro PA, Mimuro J, Sugg R, Loskutoff DJ. Retinal pigment epithelial cells produce a latent fibrinolytic inhibitor that is antigenically and biochemically related to type 1 plasminogen activator inhibitor produced by vascular endothelial cells. Exp Eye Res. 1989 Aug;49(2):195-203.
  88. Matsuda M, Sugo T, Sakata Y, Murayama H, Mimuro J, Tanabe S, et al. A thrombotic state due to an abnormal protein C. N Engl J Med. 1988 Nov 10;319(19):1265-8.
  89. Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood. 1987 Sep;70(3):721-8.
  90. Mimuro J, Sakata Y, Wakabayashi K, Matsuda M. Level of protein C determined by combined assays during disseminated intravascular coagulation and oral anticoagulation. Blood. 1987 Jun;69(6):1704-11.
  91. Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor. Blood. 1987 Feb;69(2):446-53.
  92. Yuen P, Cheung A, Lin HJ, Ho F, Mimuro J, Yoshida N, et al. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics. 1986 May;77(5):670-6.
  93. Mimuro J, Kimura S, Aoki N. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis. J Clin Invest. 1986 Mar;77(3):1006-13.
  94. Sakata Y, Mimuro J, Aoki N. Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency. Blood. 1984 Jun;63(6):1393-401.
  95. Ichinose A, Mimuro J, Koide T, Aoki N. Histidine-rich glycoprotein and alpha 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin. Thromb Res. 1984 Feb 15;33(4):401-7.